May 21, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Retatrutide induces ‘impressive’ weight loss of up to 28.3% for adults with obesity
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As Healio previously reported, retatrutide (Eli Lilly), an injectable GIP/GLP-1/glucagon receptor agonist under investigation for the treatment of obesity, type 2 diabetes and other cardio-renal-metabolic disorders, was
1,308 words~6 min read
